Methylenedi(boronic Acid Pinacol Ester)
Product Information
Molecular Formula
C13H26O4B2
Molecular Weight
267.97
Description
Bis-boronate has been reported by Morken and coworkers to be a key building block in the synthesis of enantioenriched secondary boronate esters, which undergo facile Suzuki-Miyaura coupling with minimal erosion of enantiopurity.Bis[(pinacolato)boryl]methane may be used in the preparation of trans-vinyl boronate esters, via the Boron-Wittig reaction.
Synonyms
4,4,5,5-tetramethyl-2-[(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl]-1,3,2-dioxaborolane; 4,4,5,5-tetramethyl-2-[(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl]-1,3,2-dioxaborolane
IUPAC Name
4,4,5,5-tetramethyl-2-[(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl]-1,3,2-dioxaborolane
SMILES
B1(OC(C(O1)(C)C)(C)C)CB2OC(C(O2)(C)C)(C)C
InChI
InChI=1S/C13H26B2O4/c1-10(2)11(3,4)17-14(16-10)9-15-18-12(5,6)13(7,8)19-15/h9H2,1-8H3
InChI Key
MQYZGGWWHUGYDR-UHFFFAOYSA-N
Melting Point
48 °C
Storage
2-8 °C
LogP
2.71000
Safety Information
Hazards
H315 - H319 - H335
Precautionary Statement
P261, P264, P271, P280, P302+P352, P304+P340, P305+P351+P338, P312, P321, P332+P313, P337+P313, P362, P403+P233, P405, and P501
Signal Word
Warning
Computed Properties
Hydrogen Bond Donor Count
0
Hydrogen Bond Acceptor Count
4
Rotatable Bond Count
2
Exact Mass
268.2017196 g/mol
Monoisotopic Mass
268.2017196 g/mol
Topological Polar Surface Area
36.9Ų
Heavy Atom Count
19
Formal Charge
0
Complexity
300
Isotope Atom Count
0
Defined Atom Stereocenter Count
0
Undefined Atom Stereocenter Count
0
Defined Bond Stereocenter Count
0
Undefined Bond Stereocenter Count
0
Covalently-Bonded Unit Count
1
Compound Is Canonicalized
Yes
Patents
| Publication Number | Title | Priority Date |
|---|---|---|
| WO-2022049134-A1 | Heterocyclic compounds | 2020-09-03 |
| US-2022009924-A1 | Modulators of thr-beta and methods of use thereof | 2020-07-10 |
| WO-2021233396-A1 | Azetidine cyclic ureas | 2020-05-20 |
| WO-2021210586-A1 | Condensed heterocyclic compound | 2020-04-14 |
| WO-2021097110-A1 | Therapeutic compounds and methods of use | 2019-11-13 |
| TW-202130618-A | Therapeutic compounds and methods of use | 2019-11-13 |
| WO-2021007477-A1 | Indazoles and azaindazoles as lrrk2 inhibitors | 2019-07-11 |
| TW-202116754-A | Indazoles and azaindazoles as lrrk2 inhibitors | 2019-07-11 |
| WO-2020232470-A1 | Chemical compounds | 2019-05-13 |
| TW-202108147-A | Chemical compounds | 2019-05-13 |
